NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
NewcelX management will attend the Breakthrough T1D Clinical & Research Congress in Philadelphia on October 9-11, 2026, with meetings available for researchers, investors, and potential partners. The company will discuss its lead program NCEL-101, a stem-cell-derived pancreatic islet cell therapy combined with Eledon's tegoprubart, ahead of a planned Phase 1/2a trial in Type 1 Diabetes. The update reiterates a constructive FDA Type B Pre-IND meeting from July 2026 and notes remaining IND-enabling work; no new data, financial figures, or regulatory actions were disclosed.
Key figures
- Drug Name
- NCEL-101
- Phase Of Trial
- Phase 1/2a (planned)
- Congress dates
- October 9-11, 2026
- Pre ind meeting
- Type B Pre-IND meeting with FDA completed, announced July 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.